Most importantly, the order said, examiners at the U.S. Patent and Trademark Office determined that the information at issue was irrelevant to patentability, saying it dealt with tests of the median lethal dose of the drug, not the much lower doses used by consumers.

FORBES: Wockhardt Fails To Nix Sepracor's Lunesta Patents